A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

NCT01231594 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

214

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: GSK2118436
DRUG: GSK1120212
DRUG: Other approved anti-cancer agent

Sponsor

Novartis Pharmaceuticals